BRPI0816239A2 - Derivados terapêuticos de quinolina e naftaleno - Google Patents
Derivados terapêuticos de quinolina e naftalenoInfo
- Publication number
- BRPI0816239A2 BRPI0816239A2 BRPI0816239-5A2A BRPI0816239A BRPI0816239A2 BR PI0816239 A2 BRPI0816239 A2 BR PI0816239A2 BR PI0816239 A BRPI0816239 A BR PI0816239A BR PI0816239 A2 BRPI0816239 A2 BR PI0816239A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinoline
- naphthalene
- therapeutic derivatives
- therapeutic
- derivatives
- Prior art date
Links
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 title 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95728107P | 2007-08-22 | 2007-08-22 | |
| PCT/US2008/073798 WO2009026408A1 (en) | 2007-08-22 | 2008-08-21 | Therapeutic quinoline and naphthalene derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0816239A2 true BRPI0816239A2 (pt) | 2015-02-24 |
Family
ID=39844041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816239-5A2A BRPI0816239A2 (pt) | 2007-08-22 | 2008-08-21 | Derivados terapêuticos de quinolina e naftaleno |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8614326B2 (pt) |
| EP (2) | EP2188260A1 (pt) |
| JP (2) | JP2010536872A (pt) |
| AU (1) | AU2008288898B2 (pt) |
| BR (1) | BRPI0816239A2 (pt) |
| CA (1) | CA2697284A1 (pt) |
| WO (1) | WO2009026408A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010536872A (ja) * | 2007-08-22 | 2010-12-02 | アラーガン、インコーポレイテッド | 治療用キノリンおよびナフタレン誘導体 |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| EP2879673B1 (en) * | 2012-08-06 | 2018-07-25 | Biogen MA Inc. | 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531458T2 (de) * | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| AU757059B2 (en) * | 1997-06-19 | 2003-01-30 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| US6376670B1 (en) | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US20040006135A1 (en) * | 2002-06-19 | 2004-01-08 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20040167181A1 (en) | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-3 receptor |
| MXPA05009722A (es) * | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| JP2010536872A (ja) * | 2007-08-22 | 2010-12-02 | アラーガン、インコーポレイテッド | 治療用キノリンおよびナフタレン誘導体 |
-
2008
- 2008-08-21 JP JP2010522010A patent/JP2010536872A/ja active Pending
- 2008-08-21 AU AU2008288898A patent/AU2008288898B2/en not_active Ceased
- 2008-08-21 EP EP08798329A patent/EP2188260A1/en not_active Withdrawn
- 2008-08-21 CA CA2697284A patent/CA2697284A1/en not_active Abandoned
- 2008-08-21 EP EP12192174A patent/EP2559686A1/en not_active Withdrawn
- 2008-08-21 BR BRPI0816239-5A2A patent/BRPI0816239A2/pt not_active IP Right Cessation
- 2008-08-21 WO PCT/US2008/073798 patent/WO2009026408A1/en not_active Ceased
- 2008-08-21 US US12/674,180 patent/US8614326B2/en active Active
-
2013
- 2013-11-06 JP JP2013230396A patent/JP2014062103A/ja active Pending
- 2013-12-13 US US14/105,438 patent/US20140107153A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140107153A1 (en) | 2014-04-17 |
| JP2014062103A (ja) | 2014-04-10 |
| EP2188260A1 (en) | 2010-05-26 |
| AU2008288898B2 (en) | 2014-08-07 |
| CA2697284A1 (en) | 2009-02-26 |
| WO2009026408A1 (en) | 2009-02-26 |
| US20110046177A1 (en) | 2011-02-24 |
| EP2559686A1 (en) | 2013-02-20 |
| JP2010536872A (ja) | 2010-12-02 |
| AU2008288898A1 (en) | 2009-02-26 |
| US8614326B2 (en) | 2013-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2025009I1 (no) | Oxathiapiprolin or an N-oxide or salt thereof and amisulbrom | |
| NL300891I2 (nl) | Lotilaner en zouten daarvan | |
| HRP20190016T1 (hr) | Heterociklički spojevi i njihova upotreba | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| DE602007010981D1 (de) | Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate | |
| BR112012001260A2 (pt) | conjugados de epsilon-polilisina e o emprego dos mesmos | |
| BRPI0908906A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
| LT3222615T (lt) | Psma surišantys agentai ir jų naudojimas | |
| BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
| DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
| HRP20171612T2 (hr) | Umrežujuće spojnice i njihova upotreba | |
| DOP2010000044A (es) | Derivado de oxopirazina y herbicida | |
| FI20085334A0 (fi) | Harjoitusmenetelmä ja -järjestelmä | |
| EP2122054A4 (en) | NONWOVEN PANEL AND PRODUCTION METHOD THEREOF | |
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| ZA201004305B (en) | Quinoline derivatives and their use as fungicides | |
| DK2049525T3 (da) | N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf | |
| BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
| DK2144905T3 (da) | Terapeutiske midler | |
| DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
| DK2035369T3 (da) | Terapeutiske | |
| DE602008001981D1 (de) | Stellung und therapeutische verwendung | |
| BR112012010242A2 (pt) | derivados de heteroarilpiperidina e heteroarilpiperazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |